Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

Table 3 Clinical remission according to treatment group in patients with oligoarticular JIA

	SDMARD alone n = 66	SDMARD combined n = 18	SDMARD BDMARD combined n = 25	BDMARD alone n = 3	Clinical remission n = 112	p
Persistent	61 (92)	13 (72)	17 (68)	1 (33)	92 (46)	0.003
Comorbidities ^b absence, n (%)	58 (88)	15 (83)	23 (92)	1 (33)	97 (87)	0.042
Synthetic DMARD ^a, n (%)
Metotrexate	53 (80)	9 (50)	8 (50)	0	70 (35)	0.025
First DMARD course ^c, n (%)	44 (67)	6 (28)	11 (44)	0	60 (54)	0.014
DMARD dose tapering ^a, n (%)	51 (77)	8 (44)	15 (60)	3 (100)	77 (69)	0.024

SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number;
^ap < 0,05 Statistically significant differences using the χ² test
^bComorbidities other than uveitis and not related to drug toxicity
^cFirst DMARD course = DMARD dispensed in the first place, chronologically

ISSN: 1546-0096